Identification of Human Single-Domain Antibodies against SARS-CoV-2
Yanling Wu(Shanghai Medical College of Fudan University), Tianlei Ying(Shanghai Medical College of Fudan University), Xiaolong Tian(Fudan University), Shibo Jiang(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Chao Tu(Central South University), Lu Lu(Shanghai Medical College of Fudan University), Rong Zhang(Huazhong Agricultural University), Youhua Xie(Shanghai Medical College of Fudan University), Yu Kong(Fudan University), Chenjian Gu(Washington University in St. Louis), Zhi Wang(Fudan University), Cheng Li(Huawei Technologies (China)), Zhenlin Yang(Fudan University)
Cited by 283
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
|Cell|2022|538
Mxra8 is a receptor for multiple arthritogenic alphaviruses
|Nature|2018|455